Seelos Therapeutics acquires gene therapy program license to treat Parkinson’s Disease – Proactive Investors Stocktube

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr. Raj Mehra tells Proactive Investors the clinical-stage biopharma has acquired the exclusive worldwide licensing of a gene therapy program from Duke University.

Seelos head of R&D Dr. Tim Whitaker and Dr. Jeffrey Kordower of Rush University Medical Center are working together to move the program forward.